Immuno-Oncology | Specialty

Experimental Melanoma Vaccine May Shrink Late-Stage Tumors

June 2nd 2011

An experimental melanoma vaccine gp100 peptide vaccine in combination with IL2 may shrink tumors and prevent the progression of late-stage melanoma

Juanita Madison on Handling the Provenge Process

May 23rd 2011

Juanita Madison from the Seattle Cancer Care Alliance on Handling the Provenge Treatment Process

Juanita Madison Describes the Provenge Treatment Process

May 20th 2011

Juanita Madison from Seattle Cancer Care Alliance Describes the Provenge Treatment Process

Suzanne Beauchene on the Provenge Treatment Process

May 20th 2011

Suzanne Beauchene from Seattle Cancer Care Alliance Discusses the Provenge Treatment Process from Start to Finish

Provenge Treatment Requires Multidisciplinary Care Coordination

May 6th 2011

At ONS researchers from the Seattle Cancer Care Alliance (SCCA) discussed their multidisciplinary care coordination approach for treating patients with Provenge

Ipilimumab's Unique Side Effects Require Unique Management

May 6th 2011

The FDA recently approved the immunotherapy ipilimumab (Yervoy) as a second-line treatment for patients with metastatic melanoma

Novel Therapies Prompt Push for New Paradigms to Evaluate Treatments

May 3rd 2011

As immunotherapy options grow, oncologists will need new frameworks of reference for evaluating whether patients are benefiting from the treatments

Ipilimumab's Unique Side Effects Require Unique Management

May 2nd 2011

Researchers at SFOA have examined the challenges ipilimumab's unique side-effect profile presents to oncology professionals

Dr. Gomella on Novel Prostate Cancer Immunotherapies

April 18th 2011

Dr. Leonard Gomella from the Jefferson Kimmel Cancer Center on Novel Prostate Cancer Immunotherapies

Immunotherapies: Avoiding collisions once the brake is released

April 13th 2011

Immunotherapies again made headlines in oncology last month

Provenge Gains Approval From Medicare Panel

March 31st 2011

The federal agency that determines Medicare reimbursements this week proposed to fully cover the cost of Provenge

Drugmaker Prepares to Ship New Melanoma Drug

March 29th 2011

Bristol-Myers Squibb plans to start rolling out its newly approved melanoma drug ipilimumab (Yervoy) in the next several weeks

Independence and Tenacity Anchor Immunology Pioneer

March 25th 2011

James P. Allison has never hesitated to buck the system

People in Britain Say Find Aliens, Cure Cancer

March 9th 2011

A recent poll conducted by Britain's Royal Society found that what Britons want most is a vaccine that will prevent cancer.

Politics & Policy: March 2007

August 17th 2010

The Politics and Policy page provides a concise and timely round-up of key government-related oncology and biotechnology news. Content is focused upon the public sector activities that are most likely to impact the evolving oncology and biotech industries.


August 16th 2010

Novel immunotherapy approaches to metastatic prostate cancer: Stimulating the immune response ex vivo with autologous antigen presenting cells.

Therapeutic Vaccine Improves Survival in Patients with Pancreatic Cancer

August 16th 2010

New pancreatic cancer vaccine findings were presented at the 2007 Gastrointestinal Cancers Symposium, held January 19-21 in Orlando, FL.

Welcome Back: A Dynamic and Innovative Field Deserves an Innovative Publication

August 16th 2010

The fields of oncology and biotechnology are entering a period of rapid growth and transformation. It is an exciting time for physicians, researchers, and allied healthcare professionals. We are honored to be apart of the process.

Politics & Policy: May 2007

August 12th 2010

This month's Fed Focus highlights the CDC's HPV vaccine recommendations as well as changes in Medicare coverage of ESAs for cancer-related anemia. Our reports from

We Look Forward to Hearing From You

August 11th 2010

With this and every issue of Oncology & Biotech News, we seek to provide clinicians with practical news with a global perspective. As we move forward, it is our goal to provide more information from markets outside the United States. Your input is essential to developing this publication into a useful tool for you in your daily practice.